期刊文献+

地西他滨联合改良CAG方案治疗复发、难治型急性髓系白血病的临床研究 预览 被引量:29

Clinical Resarch of Decitabine Combined with Modified CAG Regimen for Treatment of Relapsed or Refractory Acute Myeloid Leukemia
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:本研究旨在探讨地西他滨联合改良的CAG方案对复发、难治急性髓系白血病(acute myeloid leukemia,AM L)的治疗效果及不良反应。方法:回顾性分析了我科2013年1月至7月收治的10例复发、难治AM L,观察其临床特征、治疗效果及不良反应。10例患者中,男性7例,女性3例,男女比例7∶3,中位年龄45(17-61)岁。结果:10例患者经过地西他滨联合改良CAG方案治疗后7例完全缓解,1例部分缓解,2例未缓解,总缓解率80%(8/10)。白细胞数恢复中位时间18.5(5-28)d,血小板水平恢复中位时间19(12-29)d。治疗的主要副作用为骨髓抑制,10例治疗中未出现新发肺部感染等严重并发症,1例由于化疗原发肺部感染加重死亡。结论:地西他滨结合改良CAG治疗复发、难治AML具有高缓解率,低副反应的特点,值得在临床上进一步性研究。 Objective: This study was to investigate the therapeutic effectiveness and side effect of decitabine combined with modified CAG regimen for relapse or refractory patients with acute myeloid leukemia. Methods:Ten patients suffered from relapsed or refractory acute myeloid leukemia from January 2013 to July 2013 were analyzed retrospectively, and the clinical characteristics, therapeutic effectiveness, side effect were observed. Among 10 patients 7 patients were males and 3 patients were females, the ratio of male to female was 7: 3, median age was 45 ( 17 - 61 ) years. Results: After treatment by using decitabine combined with modified CAG regimen, 7 patients achived complete remission, 1 patient achived partial remission, 2 patient did not achieve remission, the overall remission rate was 80% (8/10), the median time of white blood cell count recovery was 18.5 (5 -28)days, median time of platelet level recovery was 19( 12 -29 ) days. The main side effects of treatment were myelosuppression. There was no new lung infection in all cases, one case died of exacerbation of primary lung infection after therapy. Conelution: The treatment of decitabine combined with modified CAG regimen for relapsed and refractory AML shows high response rate, low side effects, so it worthy to further clinical study.
作者 朱成英 刘世研 牛建花 张琪 杨华 朱海燕 于力 靖彧 ZHU Cheng- Ying , L1U Shi- Yan ,N1U Jian-Hua, zHANG Qi, YANG Hua , ZHU H ai- Yan, YU Li, JING Yu.1 Department of Hematology, Chinese PLA General Hospital Beijing, 100853 ; 2 Department of Oncology, Taian Mumicipal Traditional Chinese Medical Hospital, Taian 271000, Shandong Province, China ; 3 Department of Hematology, The Forth People's Hospital of Ji- nan, Jinan 250031, Shandong Province, China; 4 Department of Hematology, Gaochun County People's Hospital, Nanjing 211300, Jian- gsu Province, China
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2015年第1期88-93,共6页 Journal of Experimental Hematology
关键词 地西他滨 改良CAG 复发难治的急性髓系白血病 decitabine modified CAG relapsed and refractory acute myeloid leukemia
作者简介 通讯作者:靖彧,副主任医师,教授.E-mail:jingyu301@126.com
  • 相关文献

参考文献18

  • 1刘文,李峰敏,郭媛媛,宋辉,黄淑贤,左继爽.CAG方案治疗难治、复发性急性髓系白血病的临床疗效[J].中国煤炭工业医学杂志,2006,9(4):362-363. 被引量:5
  • 2陆道培主编..白血病治疗学[M].北京:科学出版社,1992:374.
  • 3Yamada K,Furusawa S,Saito K,et al.Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study.Leukemia,1995;9(1):10-14. 被引量:1
  • 4靖彧,朱成英,张琪,牛建花,杨华,刘世研,朱海燕,于力.地西他滨联合改良CAG方案治疗AML1-ETO阳性复发、难治急性髓系白血病的临床研究[J].中国实验血液学杂志,2014,22(5):1245-1250. 被引量:21
  • 5Saito K,Nakamura Y.Lowdose cytarabine and aclarubicin in combination with granulocyte colony stimulating factor(CAG regimen)for previously treated patients with relapsed or primary resistant acute myelogenous leukemia(AML)and previously anemia with excess blasts in transformation.Int J Hematol,2000;71:238. 被引量:1
  • 6张之南,沈悌.血液病诊断与疗效标准.第3版.北京:科学出版社,2008:99 -163. 被引量:4
  • 7Vogelstein B,Fearon ER,Hamilton SR,et al.Genetic alterations during colorectatum or development.N Engl J Med,1988;319(9):525-532. 被引量:1
  • 8Momparler RL,Bovenzi V.DNA methylation and cancer.J Cell Physiol,2000;183(2):145-154. 被引量:1
  • 9Esteller M.Dormant hypermethylated tumour suppressor genes:questions and answers.J Pathol,2005;205(2):172-180. 被引量:1
  • 10Das PM,Singal R.DNA methylation and cancer.J Clin Oncol,2004;22(22):4632-4642. 被引量:1

二级参考文献26

  • 1全国白血病化学治疗讨论会.急性白血病疗效标准[J].中华血液学杂志,1988,9(3):183-183. 被引量:51
  • 2Park LS,Waldron PE,Friend D,et al.Interleukior3,GM-CS-FandG-CSF receptor expression on cell lines and primary leukemia cells:receptor heterogeneity and relationship to growth factor responsiveness[J].Blood,1989,74:56-65 被引量:1
  • 3Wormannn B,Reuter C,Zuhisdrof M,et al.Experimental basis for the use of recombinant human granitlncyte-maerophage colonysitionrlating factor in patients with acute myeloid leukemia[J].Sc min Oncol,1994,21:39-43 被引量:1
  • 4Stone RM.The difficult problem of acute myeloid leukemia in the older adult[J].CA Cancer J Clin,2002,52:363-367 被引量:1
  • 5张之南,沈悌.血液病诊断与疗效标准.第3版.北京:科学出版社,2008:99 -163. 被引量:4
  • 6Lubbert M, Suciu S, Baila L, et al. Low-&,-,' decitabine versus best supportive care in elderly patients with intert:,'diate- or high-risk my- elodysplastic syndrome ( MDS ) ineligible for i,lensive chemotherapy : final results of the randomized phase IIl study of" the European Organ- isation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol, 2011 ;29 (15) : 1987 - 1996. 被引量:1
  • 7Lubbert M, Ruter BH, Claus R, et al. A muhicenter phase II trial of decitabine as first-line treatment for older patients with acute mye- loid leukemia judged unfit for induction chemotherapy. Haematologi- ca, 2012; 97(3) :393 -401. 被引量:1
  • 8Cashen AF, Schiller GJ, ODonnell MR,et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with a- cute myeloid leukemia. J Clin Oncol, 2010 ;28 (4) :556 - 561. 被引量:1
  • 9Guo M, I-Iu KX, Yu CL, et al. Infusion of HLA-mismatched periph- eral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood, 2011 ; ! 17 ( 3 ) : 936 - 941. 被引量:1
  • 10Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulo- cyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia, 1995 ;9( 1 ) : 10 - 14. 被引量:1

共引文献38

同被引文献183

引证文献29

二级引证文献57

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏